Lv5
948 积分 2024-06-11 加入
Local control strategies for management of NSCLC with oligoprogressive disease
6小时前
待确认
Perioperative immunotherapy in nonsmall cell lung cancer
9天前
已完结
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
1个月前
已完结
Immunotherapy plus chemoradiotherapy in cervical cancer management
2个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
2个月前
已完结
Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer
2个月前
已关闭
Continuous low‐dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study
2个月前
已完结
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
2个月前
已完结
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
2个月前
已完结
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
2个月前
已完结
皖公网安备34019202002308
